The 21st century has seen no great leaps forward in the hunt for a way to slow, stop or reverse the relentless progression of ...

Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

Researchers have devised a new way to illuminate the previously invisible oligomer clumps driving Parkinson’s disease.

Australian-founded medical technology company SYMBYX today announced compelling results from a 72-week randomized controlled ...

The world's largest-ever clinical trial of treatments to slow or stop the progression of Parkinson's disease has launched, ...

The world's largest clinical trial for Parkinson’s disease has commenced, aiming to identify treatments that can slow or halt ...

Previous applications of TUS were limited, as they were imprecise and too weak to target areas deeper in the brain. Parkinson ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Scottsdale biotech company's ...

L-R: Nishi Singh, Kimberley Gillman and Dr Anita Goff have recruited local patients in Somerset for the trial [Somerset NHS Foundation Trust] Researchers in Somerset are joining others across the UK ...

For many Tennesseans, biomarker tests are not covered by insurance, which ultimately prevents them from receiving personalized testing and treatment.